AbCellera Biologics Inc. (ABCL) Stock
5 of the hedge funds AlphaScala tracks reported ABCL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $14.93M. Company insiders reported 4 open-market buys and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own ABCL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 1.90M | $14.93M | +429% |
| Citadel Ken Griffin | 1.59M | $12.45M | +17% |
| Renaissance Technologies Jim Simons (founder) | 991K | $7.78M | -34% |
| Millennium Management Israel Englander | 519K | $4.07M | -60% |
| D.E. Shaw David Shaw | 45K | $356.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are AbCellera Biologics Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 24, 26 | Hayden Michael R | Director | BUY | 53.6K | $570K |
| Aug 18, 26 | Montalbano John S. | Director | BUY | 10.0K | $110K |
| Aug 14, 26 | Booth Andrew | Chief Financial Officer | BUY | 37.2K | $384K |
| Aug 12, 26 | Hayden Michael R | Director | BUY | 46.4K | $481K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →ABCL price chart
Powered by TradingViewWhat does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based medicines targeting unmet medical needs in endocrinology, women's health, immunology, and oncology. It employs an advanced antibody discovery platform that searches, decodes, and analyzes natural immune systems to identify therapeutic antibodies for preventing and treating diseases. Key internal programs include ABCL635, a non-hormonal medicine in Phase 2 clinical trials for moderate-to-severe vasomotor symptoms, and ABCL575, a fully human, half-life extended monoclonal antibody in Phase 1 trials for T-cell-mediated autoimmune conditions like atopic dermatitis. The company maintains strategic research collaborations and license agreements with leading pharmaceutical firms such as Eli Lilly and Company, AbbVie Inc., and Biogen Inc., facilitating milestone payments and royalties. AbCellera Biologics Inc. also advances preclinical candidates in metabolic, endocrine, and oncology areas, including T-cell engagers. Founded in 2012 and headquartered in Vancouver, Canada, it plays a vital role in accelerating antibody therapeutics through proprietary technologies like microfluidic cell culture.